What is the official ID of this bill?

The official print number for this legislation is HRES 876.

When did the legislative process begin?

The process officially started on 2022-01-19.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hres876/BILLS-117hres876ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Who is the primary sponsor?

The primary sponsor is Rep. Burgess, Michael C. [R-TX-26].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HRES 876

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Accelerating Drug Approval: Integrating FDA Processes with Operation Warp Speed

Q: What are the main provisions?

Key points include: Integrating Operation Warp Speed processes into Food and Drug Administration (FDA) operations to accelerate drug approval. Issuing guidance to help speed up the development and approval of new drugs and biological products. Utilizing existing safety and scientific data from already approved products for faster evaluation of new ones. Collecting interim data during trials to allow for parallel assessment and simultaneous approval of multiple drugs.

This resolution aims to speed up access to new drugs and biological products, such as vaccines. Citizens can expect faster market availability of innovative therapies, potentially improving treatment access and public health protection. These changes are intended to streamline approval processes, reducing the waiting time for new medical solutions.

Key points

Integrating Operation Warp Speed processes into Food and Drug Administration (FDA) operations to accelerate drug approval.

Issuing guidance to help speed up the development and approval of new drugs and biological products.

Utilizing existing safety and scientific data from already approved products for faster evaluation of new ones.

Collecting interim data during trials to allow for parallel assessment and simultaneous approval of multiple drugs.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Expressing the sense that the process behind Operation Warp Speed should be integrated within operations at the Food and Drug Administration.

Print number: HRES 876

Sponsor: Rep. Burgess, Michael C. [R-TX-26]

Process start date: 2022-01-19

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Accelerating Drug Approval: Integrating FDA Processes with Operation Warp Speed

Key Questions about Accelerating Drug Approval: Integrating FDA Processes with Operation Warp Speed